The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Changes In Market Value Are Expected For The Irritable Bowel Syndrome (IBS) Treatment Market Over The 2026–2030 Period?
The irritable bowel syndrome (ibs) treatment market size has demonstrated significant expansion in recent years. It is projected to increase from $7.41 billion in 2025 to $7.97 billion in 2026, with a compound annual growth rate (CAGR) of 7.6%. This historical growth can be ascribed to the rising prevalence of gastrointestinal disorders, increased diagnosis rates of ibs, growing awareness of digestive health, availability of prescription ibs drugs, and the expansion of hospital and retail pharmacy networks.
The market for irritable bowel syndrome (ibs) treatments is projected to experience substantial expansion over the upcoming years. Its valuation is set to reach $10.65 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.5%. This projected growth during the forecast timeframe is primarily driven by progress in precision medicine, the wider acceptance of digital health platforms, the expansion of online pharmacy channels, a heightened emphasis on microbiome research, and increased healthcare spending on chronic illnesses. Key trends anticipated within this period encompass precision medicine and microbiome-centered therapies, the integration of digital therapeutics and mobile health, AI-powered ibs diagnosis and treatment optimization, remote patient monitoring alongside smart gut health devices, and the development of sustainable, patient-focused drugs.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11978&type=smp
What Leading Drivers Are Supporting The Irritable Bowel Syndrome (IBS) Treatment Market Expansion?
The increasing occurrence of Irritable Bowel Syndrome (IBS) is anticipated to drive the expansion of the IBS treatment market. IBS is a chronic digestive condition impacting the large intestine, characterized by symptoms like constipation, diarrhea, stomach pain, and bloating, which notably diminishes life quality. This rise in IBS cases stems from lifestyle elements such as inadequate diet, stress, and environmental factors, leading to more people developing the condition. The IBS treatment market addresses patient requirements through pharmacological options like antispasmodics and gut-specific drugs, alongside non-pharmacological methods such as cognitive behavioral therapy, hypnotherapy, and dietary adjustments. As an illustration, the IBD Registry, a UK-based non-profit organization, reported reaching over 5,300 individuals with Inflammatory Bowel Disease (IBD) by December 2023, indicating an increase of over 3,000 members compared to 2022. Consequently, the increasing prevalence of IBS is a key driver for the expansion of the IBS treatment market.
What Are The Different Segment Types In The Irritable Bowel Syndrome (IBS) Treatment Market Segment Breakdown?
The irritable bowel syndrome (ibs) treatment market covered in this report is segmented –
1) By Drug Type: Eluxadoline, Alosetron, Other Drugs
2) By Indication: IBS With Constipation, IBS With Diarrhea, IBS With Alternating Constipation And Diarrhea
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
4) By End-Users: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Eluxadoline: IBS with Diarrhea (IBS-D) Treatment, Moderate IBS-D Treatment
2) By Alosetron: Severe IBS-D Treatment for Women, Refractory IBS-D Treatment
3) By Other Drugs: Prucalopride, Tenapanor, Plecanatide
What Emerging Trends Are Seen In The Irritable Bowel Syndrome (IBS) Treatment Market?
Leading companies in the irritable bowel syndrome (IBS) treatment market are increasingly focusing on integrating digital therapeutics, such as mobile applications utilizing gut-directed hypnotherapy, to improve patient engagement, enhance treatment accessibility, and facilitate symptom management. These gut-directed hypnotherapy-based mobile applications are prescription digital platforms that deliver structured hypnotherapy sessions via a smartphone interface to modify the gut–brain interaction, offering capabilities like guided behavioral therapy, real-time symptom tracking, and automated monitoring of patient progress. As an illustration, in May 2023, Launchit DTx, a Canada-based digital health commercialization company, introduced Regulora, a digital therapeutic based on gut-directed hypnotherapy. Regulora is designed to assist adults in managing abdominal pain related to irritable bowel syndrome (IBS), featuring evidence-based hypnotherapy modules, workflows for clinician prescribing, and a mobile application that monitors patient responses over time. Regulora enhances treatment access, supports self-management, and provides overall symptom relief for IBS patients by presenting a non-pharmacologic, digitally delivered therapeutic option.
Who Are The Well-Known Companies In The Irritable Bowel Syndrome (IBS) Treatment Market?
Major companies operating in the irritable bowel syndrome (ibs) treatment market are Ironwood Pharmaceuticals Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Johnson & Johnson Services Inc., AstraZeneca plc, Novartis AG, Abbott Laboratories, Eli Lilly and Company, Astellas Pharma Inc., Bausch Health Companies Inc., Sebela Pharmaceuticals Inc., Prometheus Laboratories Inc., RedHill Biopharma Ltd., Ardelyx Inc., Renexxion Ireland Ltd., 4D Pharma plc, Biora Therapeutics Inc., Salix Pharmaceuticals Ltd., Allergan plc, Synergy Pharmaceuticals Inc.
Get The Full Irritable Bowel Syndrome (IBS) Treatment Market Report:
Which Region Is The Top Contributor To The Irritable Bowel Syndrome (IBS) Treatment Market By Share?
North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the irritable bowel syndrome (ibs) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Irritable Bowel Syndrome (IBS) Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Irritable Bowel Syndrome (IBS) Treatment Market 2026, By The Business Research Company
Inflammatory Bowel Disease Treatment Market Report 2026
Bowel Management Systems Market Report
https://www.thebusinessresearchcompany.com/report/bowel-management-systems-global-market-report
Constipation Treatment Market Report
https://www.thebusinessresearchcompany.com/report/constipation-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model